Clinical Trials
- Leukemia, Pediatric Cancers, Sickle Cell Disorders
A Study of Hematopoietic Stem Cell Transplantation (HSCT) in Non-Malignant Disease Using a Reduced-Intensity Preparatory Regime
- Leukemia, Supportive Care
Early HLA Matched Sibling Hematopoietic Stem Cell Transplantation for Children With Sickle Cell Disease: A Sickle Transplant Alliance for Research (STAR) Trial
- Leukemia, Pediatric Cancers
A Phase I/II Trial of Reduced Intensity Conditioning and Familial HLA-Mismatched Bone Marrow Transplantation in Children With Non-Malignant Disorders
- Ages21 years and younger
- GenderBoth
- Lymphoma
A Randomized Phase III Trial of Consolidation With Autologous Hematopoietic Cell Transplantation Followed by Maintenance Rituximab vs. Maintenance Rituximab Alone for Patients With Mantle Cell Lymphoma in Minimal Residual Disease-Negative First Complete Remission
- Ages18 years - 70 years
- GenderBoth
- Leukemia
A Phase 2 Study of Donor-Derived Multi-Tumor-Associated Antigen Specific T Cells (MT-401) Administered to Patients With Acute Myeloid Leukemia (AML) Following Hematopoietic Stem Cell Transplantation
- Leukemia
A Controlled Multi-Arm Ph1 Study Evaluating the Safety and Feasibility of TCR Engineered Donor TCells Targeting HA1 (TSC-100) or HA2 (TSC-101) in HLA-A0201 Positive Patients Undergoing Haploidentical Allogeneic Stem Cell Transplantation
- Liver, HIV/AIDS, Infectious Disease
HOPE in Action Trial of HIV+ Deceased Donor Liver Transplants for HIV+ Recipients
- Ages18 years and older
- GenderBoth
- HIV/AIDS
Kidney Transplantation in Recipients and Donors with HIV: Long Term Follow up Study
- Ages18 years and older
- GenderBoth
- Kidney & Urinary Tract, HIV/AIDS
HOPE in Action Prospective Multicenter, Clinical Trial of Deceased HIVD+ Kidney Transplants for HIV+ Recipients
- Ages18 years and older
- GenderBoth
- Leukemia
A Phase II Pilot Trial to Estimate Survival After a Non-total Body Irradiation (TBI) Based Conditioning Regimen in Patients Diagnosed With B-acute Lymphoblastic Leukemia (ALL) Who Are Pre-allogeneic Hematopoietic Cell Transplantation (HCT) Next-generation-sequence (NGS) Minimal Residual Disease (MRD) Negative
- Ages1 year - 25 years
- GenderBoth